NEO

Netherlands Epidemiology of Obesity Study

Project Coordinator

Renée de Mutsert, PhD   

Principal InvestigatorProf. dr F.R. Rosendaal
CooperationMany Departments of the Leiden University Medical Center
Informationwww.neostudie.nl

The Netherlands Epidemiology of Obesity Study (NEO) is a population-based cohort study in men and women aged 45 to 65 years and with overweight (BMI at least 27 kg/m2) from the Leiden region in The Netherlands. The NEO study is designed to study the pathways that lead to common diseases and conditions in persons with overweight. The interrelationships between common diseases, and between newly identified determinants with traditional, established risk factors and interrelationships between various diseases and conditions are addressed.

Participants have been recruited via general practitioners in the area of Leiden, through advertisements in local newspapers and posters in public areas, and via the registers of three municipalities surrounding Leiden (Katwijk, Leiderdorp and Teylingen).

Participants completed multiple validated questionnaires at home with demographic, lifestyle, and clinical information. At the NEO study center the participants underwent an extensive physical examination including anthropometry, blood pressure, blood sampling (fasting, and 30 minutes and 2.5 hours after a mixed meal), urine sampling, resting EKG, carotid artery IMT, and pulmonary function tests. In random subsets of participants visceral fat, liver triglyceride content, and pulse wave velocity of the aorta has been measured by MRI, as well as assessment of resting energy expenditure, DXA, and accelerometry combined with continuous heart rate measurement.

Participants gave informed consent to be followed for manifestation of clinical diseases and conditions through the records of their general practitioners and medical specialists. If applicable, diseases and conditions will be verified by hospital records. Important outcomes of interest in the NEO study are insulin resistance and type 2 diabetes mellitus, dyslipidemia, cardiovascular diseases, venous thrombosis, asthma and chronic obstructive pulmonary disease, renal failure, osteoarthritis, cirrhosis, and mortality.